Original Articles: Hepatology

Neurodevelopmental Outcomes in Children With Inherited Liver Disease and Native Liver

Leung, Daniel H.^∗; Sorensen, Lisa G.^†; Ye, Wen^‡; Hawthorne, Kieran^§; Ng, Vicky L.^||; Loomes, Kathleen M.^¶; Fredericks, Emily M.^#; Alonso, Estella M.^∗∗; Heubi, James E.^††; Horslen, Simon P.^‡‡; Karpen, Saul J.^§§; Molleston, Jean P.^||||; Rosenthal, Philip^¶¶; Sokol, Ronald J.^##; Squires, Robert H.^∗∗∗; Wang, Kasper S.^†††; Kamath, Binita M.^‡‡‡; Magee, John C.^§§§

Author Information

^∗Division of Pediatric Gastroenterology, Hepatology and Nutrition, Texas Children's Hospital, Baylor College of Medicine, Houston, TX

^†Department of Child & Adolescent Psychiatry, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL

^‡Department of Biostatistics, University of Michigan

^§ArborResearch Collaborative for Health, Ann Arbor, MI

^||Transplant and Regenerative Medicine Center, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

^¶Pediatric Gastroenterology, Children's Hospital of Philadelphia, Philadelphia, PA

^#CS Mott Children's Hospital, University of Michigan Medical School, Ann Arbor, MI

^∗∗Ann and Robert H. Lurie Children's Hospital and Northwestern University, Chicago, IL

^††Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

^‡‡Division of Gastroenterology and Hepatology, Seattle Children's, Seattle, WA

^§§Pediatrics, Emory University, Children's Healthcare Atlanta, Atlanta, GA

^||||Pediatric Gastroenterology, Hepatology and Nutrition, James Whitcomb Riley Hospital for Children, Indianapolis, IN

^¶¶Pediatrics and Surgery, University of California San Francisco, San Francisco, CA

^##Pediatric Gastroenterology, Hepatology and Nutrition, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, CO

^∗∗∗Pediatrics, University of Pittsburgh, Pittsburgh, PA

^†††Children's Hospital Los Angeles, Los Angeles, CA

^‡‡‡Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

^§§§Surgery, University of Michigan School of Medicine, Ann Arbor, MI.

Address correspondence and reprint requests to Daniel H. Leung, MD, FAASLD, Associate Professor of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, Gastroenterology, Hepatology, and Nutrition, Director of Hepatology and Liver Transplant Medicine, Medical Director, Viral Hepatitis Program; 6621 Fannin St, MWT 1010, Houston, TX 77030 (e-mail: [email protected]).

Received 15 February, 2021

Accepted 6 July, 2021

Trial ID #: Clinicaltrials.gov: NCT00571272.

Sources of Funding: This work was supported by funding from the Alpha-1 Foundation (University of Colorado Denver and Saint Louis University School of Medicine) and by U01 grants from the National Institute of Diabetes, Digestive and Kidney Diseases and UL1 grants from the National Center for Advancing Translational Sciences (NCATS): DK062445 [Mt. Sinai School of Medicine], DK062497 and UL1 TR000077 [Cincinnati Children's Hospital Medical Center, University of Cincinnati], DK103149 [Texas Children's Hospital], DK062470 [Children's Healthcare of Atlanta, Emory University], DK062481 and UL1 TR000003 [The Children's Hospital of Philadelphia, University of Pennsylvania], DK062456 [University of Michigan], DK084536 and UL1 TR000006 [Riley Hospital for Children, Indiana University], DK084575 and UL1 TR000423 [Seattle Children's Hospital, University of Washington], DK062500 and UL1 TR000004 [UCSF Children's Hospital, University of California San Francisco], DK062503 and UL1 TR000424 [Johns Hopkins School of Medicine], DK062466 and UL1 TR000005 [Children's Hospital of Pittsburgh, University of Pittsburgh], DK062453 and UL1 TR002535 [University of Colorado Denver, Children's Hospital Colorado], DK062452 and UL1 TR000448 [Washington University School of Medicine, St. Louis, St. Louis Children's Hospital], DK084538 and UL1 TR000130 [Children's Hospital Los Angeles, University of Southern California], DK062436 and UL1 TR000150 [Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University], DK103140 [University of Utah], DK103135 [Hospital for Sick Children (Toronto)].

Conflicts of Interest: D.H.L. reports grant/research support from Abbvie, Gilead, and CF Foundation; he also serves on advisory panels for Merck and Gilead. B.M.K. is a consultant for Mirum, Albireo and Audentes; she has unrestricted educational grants from Mirum and Albireo. V.L.N. is a consultant for Albireo. P.R. reports grants from Gilead, Merck, BMS, AbbVie, Travere Therapeutics, Albireo, and Mirum, Arrowhead; and serving as a consultant for Gilead, Mirum, Albireo, Audentes, and Vertex. R.J.S. reports consulting for Albireo, Mirum/Shire, and Retrophin (all <$10,000 per year). K.M.L. reports consulting for Albireo, Mirum and Retrophin (now known as Travere Therapeutics). The remaining authors report no conflicts of interest. The study sponsors did not have a role in study design; collection, analysis, and interpretation of data; writing of the report; or the decision to submit the paper for publication.

Dr Heubi passed away on August 4, 2021, prior to publication of this article.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text, and links to the digital files are provided in the HTML text of this article on the journal's Web site (www.jpgn.org).

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0

Journal of Pediatric Gastroenterology and Nutrition 74(1):p 96-103, January 2022. | DOI: 10.1097/MPG.0000000000003337

Open
SDC

Abstract

An infographic is available for this article at:https://links.lww.com/MPG/C554.

What Is Known

Alagille syndrome, progressive familial intrahepatic cholestasis, and alpha-1 antitrypsin deficiency represent the most common inherited cholestatic liver disorders in children. Whether specific inherited liver disorders are associated with more neurodevelopmental impairment than others is unknown.

What Is New

In a multi-center observational study, participants with Alagille syndrome were at increased risk of lower Full Scale Intelligence Quotient (FSIQ); malnutrition and liver disease severity were significantly associated with FSIQ and represent potential targets for early intervention.

Children with inherited pediatric liver diseases, such as Alagille syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), and alpha-1 antitrypsin deficiency (A1AT), are unique and often present with cholestasis or significant fibrosis at an early age ^(1–3). ALGS is an autosomal dominant syndrome with cholestasis and extrahepatic involvement, including cardiac, vascular, and renal abnormalities ⁽⁴⁾. PFIC is a family of autosomal recessive monogenic liver diseases with altered phospholipid or bile salt transport ⁽⁵⁾. A1AT is inherited in an autosomal co-dominant fashion with misfolding and defective secretion of A1AT and can result in cirrhosis and lung disease ⁽⁶⁾. These represent the most common inherited cholestatic liver disorders in children, but each has a different etiology and clinical presentation. Whether specific inherited liver disorders have more neurodevelopmental impairment than others is unknown. Neurodevelopmental outcomes in this distinctive cohort of inherited pediatric liver diseases have been limited to small, post-transplant or single-center studies ^(7–9). Early predictors of abnormal neurodevelopment in these liver disorders could be used to identify high-risk individuals, potentially leading to interventions and improvement in long-term neurocognitive outcomes. Within the National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health (NIDDK/NIH)-supported Childhood Liver Disease Research Network (ChiLDReN), intelligence testing was completed in a cohort of children with these disorders surviving with their native livers. We hypothesized that children with ALGS, A1AT, and PFIC would demonstrate lower mean intelligence quotient (IQ) relative to test norms, and that specific demographic and clinical features would predict increased risk. Further, we hypothesized that patients with ALGS may have greater neurodevelopmental deficits due to extrahepatic involvement.

METHODS

Study Population

The Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC; Clinicaltrials.gov:NCT00571272) is a prospective study enrolling participants with ALGS, A1AT, or PFIC at 14 clinical sites from birth to age 25 years with annual follow-up. Detailed inclusion and exclusion criteria for LOGIC are listed in the Appendix, https://links.lww.com/MPG/C555. The Wechsler Preschool and Primary Scale of Intelligence-III (WPPSI-III) ⁽¹⁰⁾ and Wechsler Intelligence Scale for Children-IV (WISC-IV) ⁽¹¹⁾ were administered once to English-speaking participants ages 3–5 years and 6–16 years, respectively, following enrollment. Informed consent was obtained from parents or guardians at all sites; the protocol was implemented under institutional review board approval.

Intelligence Testing—Measures of Intelligence Quotient

Composite scores for WPPSI-III and WISC-IV include Full Scale IQ (FSIQ), Verbal IQ (VIQ)/Verbal Comprehension Index (VCI), and Performance IQ (PIQ)/Perceptual Reasoning Index (PRI). Processing Speed Index (PSI) and Working Memory Index (WMI) were only available in participants >6 years old (WISC-IV only) ^(10,11). Although newer versions of both measures became available during study enrollment (WPPSI-IV in 2012; WISC-V in 2014), we continued using prior versions to preserve data integrity and avoid challenges in interpreting combined data.

Risk Factors

Potential predictors of neurodevelopmental outcome included disease type, demographics, medical history, current pruritus status, history of xanthomas, renal involvement, cardiac disease severity, laboratory results, aspartate aminotransferase (AST) to platelet ratio index (APRI) ⁽¹²⁾, Fibrosis-4 (FIB-4) ⁽¹³⁾, and growth parameters ⁽¹⁴⁾ obtained ±6 months of intelligence testing. Race and ethnicity were parent-reported. Clinically-evident portal hypertension (CEPH), as defined by ChiLDReN ⁽¹⁵⁾, was analyzed in subgroups of definite (dCEPH), possible (pCEPH), and absent CEPH (aCEPH). Minimal hepatic encephalopathy (MHE) was not captured in the LOGIC study.

Renal involvement and severe cardiac disease were defined a priori (Fig. 1, Supplemental Digital Content [SDC], https://links.lww.com/MPG/C556). As an exploratory analysis, we examined the effect of JAG1, ATP8B1, ABCB11, and ABCB4 genetic mutation class and PI ZZ or PI SZ serum protein phenotype on IQ score in ALGS, PFIC, and A1AT patients, respectively.

Statistical Methods

Descriptive statistics of patient characteristics were calculated for the total study population and each disease type separately. Categorical and continuous variables were compared across disease groups using chi-square tests and Wilcoxon or Kruskal-Wallis tests. Pairwise comparisons between disease groups were conducted when an overall significant difference was found. Composite IQ scores are standardized, with a mean of 100 and standard deviation (SD) of 15. We compared distribution of IQ scores by disease group to normal distribution using Kolmogorov-Smirnov tests. IQ scores were categorized into bins by z score: FSIQ >100 (z > 0), 85–99 (−1 < z < 0), 70–84 (−2 < z < −1), and <70 (z < −2) and compared with expected percentages within each bin in the normal distribution using chi-square tests ^(10,11). Linear regression was performed to study the association between continuous FSIQ and each risk factor, adjusting for parental education, stratified by disease group. Skewed laboratory variables were modeled on the log base 2 scale to improve model fit. Both original P values and adjusted P values using the adaptive Hochberg correction for family-wise error rate are reported ⁽¹⁶⁾.

RESULTS

Study Population

Between November 2007 and April 2018, 647 of 809 LOGIC participants with native liver were eligible for IQ testing. Two hundred and fifteen children (33.2% of eligible patients) completed testing (ALGS n = 70, PFIC n = 43, A1AT n = 102) at a mean age of 8.2 years (SD 3.8) (Table 1). Reasons for exclusion are detailed in Figure 2, SDC, https://links.lww.com/MPG/C556. WPPSI-III and WISC-IV testing was completed in 78 and 137 participants, respectively. Compared with eligible but not tested LOGIC participants (Table 1, SDC, https://links.lww.com/MPG/C556), A1AT participants who completed testing were more likely to be male; PFIC participants were older (both P< 0.05). Detailed reasons for non-participation by eligible patients were not available.

TABLE 1 - Demographics and clinical characteristics of children with inherited cholestatic liver disease

Variable	ALGS (N = 70)		PFIC (N = 43)		A1AT (N = 102)		Total (N = 215)		Overall P value
Demographics and clinical variables	n	Frequency (%) or mean (SD)	n	Frequency (%) or mean (SD)	n	Frequency (%) or mean (SD)	n	Frequency (%) or mean (SD)
Age at testing (y)	70	8.7 (3.7)	43	8.5 (4.3)	102	7.7 (3.5)	215	8.2 (3.8)	0.207
Female	70	25 (35.7%)	43	22 (51.2%)^c	102	29 (28.4%)^c	215	76 (35.3%)	0.033
Race
White	67	52 (77.6%)^b	43	32 (74.4%)^c	102	94 (92.2%)^b ^, ^c	212	178 (84.0%)	0.008
Black		6 (9.0%)		5 (11.6%)		0 (0.0%)		11 (5.2%)
Other^∗		9 (13.4%)		6 (14.0%)		8 (7.8%)		23 (10.8%)
Hispanic	70	12 (17.1%)^b	42	5 (11.9%)	100	5 (5.0%)^b	212	22 (10.4%)	0.036
Parental education
High school equivalent or less	66	14 (21.2%)	39	12 (30.8%)^c	93	11 (11.8%)^c	198	37 (18.7%)	0.032
Some college/trade school or more		52 (78.8%)		27 (69.2%)		82 (88.2%)		161 (81.3%)
Test type
WPPSI-III (age 3–5)	70	19 (27.1%)	43	17 (39.5%)	102	42 (41.2%)	215	78 (36.3%)	0.151
WISC-IV (age 6–16)		51 (72.9%)		26 (60.5%)		60 (58.8%)		137 (63.7%)
Height-for-age z score	68	−1.51 (1.18)^a ^, ^b	43	−0.90 (1.24)^a ^, ^c	97	0.45 (1.03)^b ^, ^c	208	−0.47 (1.43)	<.001
Weight-for-age z score	66	−1.34 (1.25)^a ^, ^b	43	−0.47 (1.14)^a ^, ^c	99	0.71 (1.05)^b ^, ^c	208	−0.18 (1.45)	<.001
BMI z score	66	−0.55 (1.29)^a ^, ^b	43	0.23 (1.03)^a ^, ^c	96	0.70 (1.04)^b ^, ^c	205	0.20 (1.25)	<.001
Pruritus
None/mild	68	42 (61.8%)^b	43	32 (74.4%)^c	99	98 (99.0%)^b ^, ^c	210	172 (81.9%)	<.001
Active/bleeding		26 (38.2%)		11 (25.6%)		1 (1.0%)		38 (18.1%)
History of xanthoma(s)	69	18 (26.1%)^a ^, ^b	43	1 (2.3%)^a	102	0 (0.0%)^b	214	19 (8.9%)	<.001
CEPH
aCEPH	70	46 (65.7%)^b	43	34 (79.1%)	102	79 (77.5%)^b	215	159 (74.0%)	0.100
pCEPH		14 (20.0%)		5 (11.6%)		7 (6.9%)		26 (12.1%)
dCEPH^† ^, ^‡		10 (14.3%)		4 (9.3%)		16 (15.7%)		30 (14.0%)
Total bilirubin (mg/dL)	63	1.6 (0.7, 3.4)^a ^, ^b	43	0.7 (0.4, 1.9)^a ^, ^c	95	0.4 (0.3, 0.7)^b ^, ^c	201	0.6 (0.4, 1.6)	<.001
GGTP (U/L)	49	353 (233, 869)^a ^, ^b	35	19 (12, 48)^a ^, ^c	80	31 (19, 91)^b ^, ^c	164	55 (19, 275)	<.001
AST (U/L)	64	153 (102, 192)^a ^, ^b	43	60 (36, 113)^a	97	62 (42, 93)^b	204	77 (48, 147)	<.001
ALT (U/L)	63	179 (119, 242)^a ^, ^b	43	50 (32, 106)^a	96	68 (43, 110)^b	202	90 (46, 179)	<.001
Alkaline phosphatase (U/L)	61	506 (369, 653)^b	42	474 (331, 553)^c	93	255 (211, 337)^b ^, ^c	196	347 (236, 513)	<.001
Platelet count (× 10³/mm³)	58	244 (171, 338)	36	305 (206, 377)	88	263 (201, 324)	182	266 (189, 333)	0.333
INR	55	1.0 (0.9, 1.1)^b	33	1.0 (1.0, 1.1)	64	1.1 (1.0, 1.1)^b	152	1.0 (1.0, 1.1)	0.016
Albumin (g/dL)	61	4.3 (4.0, 4.5)^b	42	4.2 (3.9, 4.5)^c	95	4.4 (4.1, 4.7)^b ^, ^c	198	4.3 (4.0, 4.6)	0.012
BUN (mg/dL)	45	16 (14, 19)^a ^, ^b	31	12 (9, 14)^a	56	12 (11, 15)^b	132	13 (11, 16)	<.001
Creatinine (mg/dL)	49	0.44 (0.37, 0.50)^a	32	0.35 (0.30, 0.50)^a ^, ^c	60	0.40 (0.33, 0.54)^c	141	0.40 (0.30, 0.50)	0.042
Hemoglobin (g/dL)	57	12.9 (12.0, 13.5)^b	36	12.6 (11.8, 13.5)^c	89	13.5 (13.0, 14.0)^b ^, ^c	182	13.1 (12.3, 13.9)	<.001
APRI	58	1.39 (0.98, 2.96)^a ^, ^b	36	0.52 (0.33, 0.96)^a	87	0.64 (0.37, 1.32)^b	181	0.83 (0.41, 1.83)	<.001
<1		15 (25.9%)^a ^, ^b		28 (77.8%)^a		63 (72.4%)^b		106 (58.6%)
1–1.5		16 (27.6%)		1 (2.8%)		4 (4.6%)		21 (11.6%)
>1.5		27 (46.6%)		7 (19.4%)		20 (23.0%)		54 (29.8%)
FIB-4	57	0.41 (0.21, 0.89)^a ^, ^b	36	0.22 (0.14, 0.38)^a	86	0.24 (0.13, 0.36)^b	179	0.26 (0.14, 0.53)	0.003

Overall P-value refers to a simultaneous comparison of all three disease groups. P < 0.05 indicates a significant difference in at least one group compared with the others.A1AT = alpha one antitrypsin deficiency; aCEPH = absent clinically-evident portal hypertension; ALGS = Alagille syndrome; ALT = alanine aminotransferase; APRI = AST to platelet ratio index; AST = aspartate aminotransferase; BMI = body mass index; BUN = blood urea nitrogen; CEPH = clinically-evident portal hypertension; dCEPH = definite clinically-evident portal hypertension; FIB-4 = fibrosis-4; GGTP = gamma glutamyl transpeptidase; INR = international normalized ratio; pCEPH = possible clinically-evident portal hypertension; PFIC = progressive familial intrahepatic cholestasis.

^∗Other race includes Asian, American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, other, multiracial, or unknown.

^†Renal involvement was defined as dysplastic kidney, single kidney, renal tubular acidosis, or other renal abnormality reported on initial history.

^‡Bass LM, Shneider BL, Henn L, et al. Clinically evident portal hypertension: an operational research definition for future investigations in the pediatric population. J Pediatr Gastroenterol Nutr 2019;68:763–767.

^aALGS versus PFIC, P < 0.05.

^bALGS versus A1AT, P < 0.05.

^cPFIC versus A1AT, P < 0.05.

Demographic and Clinical Variables

Disease groups were similar in age at testing and frequency of IQ test version administered but differed demographically (Table 1). A1AT participants were more white (92.2% vs 74.4% PFIC and 77.6% ALGS, P < 0.05), less Hispanic (5.0% vs 17.1% ALGS, P < 0.05), and had higher parental education (88.2% with some college or more vs 69.2% PFIC, P < 0.05).

Patients with ALGS had significantly lower mean z scores for height (−1.51 [SD 1.18]), weight (−1.34 [SD 1.25]), and BMI (−0.55 [SD 1.29]) than PFIC and A1AT (all pairwise P < 0.05). Median APRI was 1.39 in ALGS, significantly higher than PFIC (0.52; P < 0.05) and A1AT (0.64; P < 0.05). Median FIB-4 in ALGS was 0.41, significantly higher than PFIC (0.22; P < 0.05) and A1AT (0.24; P < 0.05). Total bilirubin, gamma glutamyl transferase (GGT), aspartate (AST), and alanine aminotransferases (ALT) were significantly higher in patients with ALGS versus PFIC and A1AT; alkaline phosphatase (ALP) was the lowest in A1AT versus PFIC and ALGS (Table 1). Among PFIC participants, 41% (n = 17/41 with data) had undergone partial external biliary diversion surgery before IQ testing. Platelet count was not significantly different among groups. Active or bleeding pruritus was prevalent in ALGS (38.2%) and PFIC (25.6%), but almost completely absent in A1AT (1.0%). Except for one PFIC participant, only ALGS participants had xanthomas. Differences among groups in international normalized ratio (INR), albumin, hemoglobin, and creatinine were statistically but not clinically significant; mean values were within normal range.

Intelligent Quotient Scores

The ALGS group scored significantly lower than test norms on all Wechsler composite scores (all P values < 0.02) except PIQ/PRI (Table 2). The A1AT group scored lower than test norms on WMI and PSI, but higher on VIQ/VCI and PIQ/PRI (P < 0.03). The PFIC group mean composite scores did not differ from population norms. The ALGS group had lower mean FSIQ, VIQ/VCI, and PIQ/PRI compared with A1AT (P < 0.05). These differences persisted after adjustment for parental education using linear regression models. PFIC and A1AT groups did not differ significantly on any composite scores.

TABLE 2 - WPPSI-III/WISC-IV IQ scores by disease group

	ALGS (N = 70)		PFIC (N = 43)		A1AT (N = 102)
WPPSI-III/WISC-IV composite score	n	Mean (SD)	n	Mean (SD)	n	Mean (SD)	Overall P value
Full Scale IQ (FSIQ)	69	94.2 (16.7)^∗	43	98.9 (14.4)	102	100.8 (16.3)^∗	0.030
P value versus norms		0.020		>0.250		>0.250
Verbal IQ/Verbal Comprehension Index (VIQ/VCI)	69	95.0 (16.1)^∗	43	100.4 (11.3)	102	102.5 (15.2)^∗	0.016
P value versus norms		0.008		>0.250		0.027
Performance IQ/Perceptual Reasoning Index (PIQ/PRI)	70	96.9 (16.1)^∗	43	100.7 (16.3)	102	102.9 (17.3)^∗	0.033
P value versus norms		>0.250		>0.250		0.015
Working Memory Index (WMI)^†	51	92.6 (18.2)	26	97.3 (13.7)	60	94.3 (14.0)	0.601
P value versus norms		0.003		>0.250		0.021
Processing Speed Index (PSI)^†	51	93.1 (15.2)	26	96.2 (14.5)	60	91.8 (16.6)	0.527
P value versus norms		0.017		>0.250		0.002

A1AT, alpha one antitrypsin deficiency; ALGS, Alagille syndrome; IQ, intelligence quotient; PFIC, progressive familial intrahepatic cholestasis; WISC-IV, Wechsler Intelligence Scale for Children-IV; WPPSI-III, Wechsler Preschool and Primary Scale of Intelligence-III.

^∗ALGS versus A1AT, P < 0.05. No significant differences found between ALGS versus PFIC or PFIC versus A1AT (P > 0.05 for all).

^†WMI and PSI are only available for WISC-IV.

Distribution of scores was significantly shifted downward from expected for FSIQ and WMI in ALGS (P < 0.01), and for WMI and PSI in A1AT (P < 0.05, Fig. 1, Table 2, SDC, https://links.lww.com/MPG/C556). In contrast, distribution of VIQ/VCI and PIQ/PRI in A1AT (P < 0.01) was shifted higher than expected, with a larger proportion of patients scoring at or above average than population norms would suggest. The only observed between-group differences were in VIQ/VCI and PIQ/PRI (Table 2, SDC, https://links.lww.com/MPG/C556); ALGS score distribution had a larger proportion in the below-average categories and smaller proportions in the average and above categories compared with A1AT (P < 0.05).

FIGURE 1:
Distribution of IQ scores by disease group. Distribution of Full Scale and subdomain IQ scores are binned by z score and compared to expected percentages from the normal distribution using chi-square tests. IQ = intelligent quotient.

Ten out of the 214 (4.7%) in our overall study population had FSIQ score <70 (at risk of intellectual disability) (vs 2.3% in the population norms), with 8.7% in ALGS, 0% in PFIC, and 3.9% in A1AT.

Risk Factor Analysis

Figure 2 shows risk factors significantly associated (before adjustment for multiple comparisons) with FSIQ in at least one disease group identified using univariate analysis adjusting for parental education (Table 3, SDC, https://links.lww.com/MPG/C556). Having a parent with some college or more is associated with 11.9 and 16.6 points higher FSIQ compared with less education in A1AT and PFIC (P < 0.05), respectively. In PFIC, a doubling of total bilirubin and a 1 g/dL decrease in either albumin or hemoglobin were significantly associated with 3.2 (95% confidence interval [CI]: 0.5, 5.9), 12.7 (95% CI: 4.5, 20.9), and 3.7 (95% CI: 0.3, 7.2) lower FSIQ, respectively. In ALGS, a doubling of alkaline phosphatase was significantly associated with 6.8 points lower FSIQ (95% CI: 0.3, 13.4), and a 1 g/dL decrease in albumin was significantly associated with 10.9 points lower FSIQ (95% CI: 1.8, 20.1). In A1AT participants, a one-unit increase in BMI-for-age z score was significantly associated with 3.1 points lower FSIQ (95% CI: 0, 6.1). The only variable that remained significant after adjustment for multiple testing was parental education in the A1AT group (Table 3, SDC, https://links.lww.com/MPG/C556). Variables studied that were not significantly associated with FSIQ included CEPH status, pruritus, and age at testing.

FIGURE 2:
Univariate predictors of continuous FSIQ. Linear regression adjusted for parental education was performed, stratified by disease. Variables associated with FSIQ at P < 0.05 (unadjusted) in at least one disease group are shown. P values adjusted for multiple comparisons are also included for reference. FSIQ = Full Scale Intelligent Quotient.

In an exploratory sub-analysis among ALGS, cardiac disease severity (n = 16 severe vs n = 53 mild or none) was not significantly associated with FSIQ (Fig. 1, SDC, https://links.lww.com/MPG/C556). Renal involvement was reported in 21.4% of ALGS patients (Table 4, SDC, https://links.lww.com/MPG/C556) and was not significantly associated with FSIQ.

The majority of ALGS patients (94%) had JAG1 mutation testing performed. Among the 60 confirmed JAG1 genotypes (Table 4, SDC, https://links.lww.com/MPG/C556), splicing mutations were most common (n = 27, 45%) followed by protein truncation (n = 16), missense (n = 13), and total gene deletion (n = 4). The mean FSIQ of three participants with total gene deletion and an FSIQ score available was the lowest among all JAG1 mutation types (Fig. 3a, SDC, https://links.lww.com/MPG/C556). Mean FSIQ did not differ among the three PFIC genotypes (ATP8B1, ABCB11, and ABCB4) and variant class types. All A1AT patients with FSIQ < 85 (12.8%) had ZZ phenotype (Fig. 3b, SDC, https://links.lww.com/MPG/C556), except for one with SZ genotype.

DISCUSSION

In this prospective multi-center study, IQ deficits in children ages 3–16 years with inherited cholestatic liver disorders and native liver were greatest among participants with ALGS. Participants with ALGS scored significantly lower than test norms on the WPPSI-III/WISC-IV in FSIQ, VIQ/VCI, WMI, and PSI, but not PIQ/PRI. In contrast, PFIC and A1AT showed fewer IQ deficits. PFIC composite scores were similar to population norms; A1AT scores were lower than test norms only for WMI and PSI. Importantly, among ALGS participants, the frequency of FSIQ < 85 was nearly double the expected and the frequency of FSIQ < 70 (at risk for intellectual disability) was greater than twice expected. In contrast, distribution of FSIQ scores among the A1AT and PFIC groups was no different than population norms. FSIQ, VIQ/VCI, and PIQ/PRI were the lowest among children with ALGS and significantly lower when compared with A1AT.

In addition, we identified socioeconomic and medical risk factors for lower FSIQ among these cholestatic diseases, including lower parental education and measures of nutrition, although specific predictors varied by disease. Surrogates of liver disease progression, namely APRI, FIB-4, and portal hypertension status, were different in ALGS but were not significant predictors of FSIQ. The association of lower albumin with lower FSIQ in ALGS and PFIC may reflect differences in degree of cirrhosis or portal hypertension and nutritional status, as both had negative weight and height z scores, consistent with suboptimal growth. Similarly, in a biliary atresia (BA) study, low length z scores at time of testing, a marker of growth stunting, was an independent risk factor for combined BSID-II/Bayley-III variables of physical/motor impairment and low weight z score for mental/cognitive/language impairment at age 1 year ⁽¹⁷⁾, highlighting nutritional supplementation as a potential intervention.

Infants and toddlers with cholestatic liver disease are at high risk for neurodevelopmental deficits ^(9,18). This was confirmed in a recent multi-center study showing increased risk for delays at ages 12 and 24 months in children with BA with native livers, despite successful hepatoportoenterostomy (HPE) ⁽¹⁷⁾. Furthermore, those with unsuccessful HPE (persistent cholestasis or more severe disease) were >4 times more likely to have neurodevelopmental impairment compared with those with successful HPE ⁽¹⁷⁾. In contrast to BA, however, neither GGT nor total bilirubin was a predictor of poor neurodevelopmental outcome in ALGS (or any subgroup) despite being 4-fold and 10-fold higher respectively, than the A1AT group; however, ALGS participants had the highest mean APRI, FIB-4, AST, and ALT, all markers of progressive liver disease. In a parallel study to this one, health-related quality of life was impaired in children with ALGS compared with healthy children and A1AT-affected children and positively correlated with better growth and inversely with total bilirubin ⁽¹⁹⁾. The association of higher alkaline phosphatase levels with lower FSIQ in ALGS is noteworthy. It is possible that elevations in alkaline phosphatase may be a surrogate marker of more severe cholestasis. High alkaline phosphatase can also be related to rapid bone growth or bone disorders (eg, osteopenia or hepatic osteodystrophy). Bone mineral deficits are prevalent in children with ALGS, correlating in severity with degree of cholestasis and fracture history ⁽²⁰⁾. There is also evidence for intrinsic trabecular and cortical bone abnormalities in ALGS children ⁽²¹⁾, further supporting a role for JAG1 and the Notch pathway in skeletal bone development ⁽²²⁾.

Wechsler composite score profiles provide more detailed neurodevelopmental outcomes. The ALGS group had FSIQ, VIQ/VCI, and PIQ/PRI scores consistently 6–7.5 points lower than A1AT, with a significantly higher proportion of below average scores than test norms and A1AT. Higher VIQ/VCI and PIQ/PRI scores in A1AT likely reflect the specific demographic characteristics (>88% some college or more) and cannot be generalized to the A1AT population at-large. Nevertheless, there appear to be disease-specific neurodevelopmental profiles. WMI and PSI (low in ALGS and A1AT) are more vulnerable to the influence of attention, ability to engage, illness, fatigue, and central nervous system (CNS) injury ^(23–25). Processing speed and working memory, defined as “the ability to actively maintain information in conscious awareness, perform some operation or manipulation with it, and produce a result,” are critical components in fluid reasoning ⁽¹¹⁾. These findings suggest that ALGS patients may be more globally impacted by their disease, whereas A1AT patients may have specific weaknesses in attention and executive functioning. Patients with ALGS have additional comorbidities, including physical disabilities ⁽²⁶⁾ and severe pruritus, which may disrupt sleep, school attendance, mood, and concentration ⁽²⁷⁾.

Patients with ALGS may be at greater risk for neurodevelopmental deficits due to a combination of factors shared with other cholestatic liver diseases (stunted growth/nutritional deficits, severity of liver disease and associated complications) in addition to extra-hepatic factors such as intracranial vascular anomalies. While our sub-analyses did not demonstrate a significant association between cardiac disease severity or JAG1 mutation class with neurodevelopmental delay, median FSIQ among ALGS were lower in those with gene deletions and more severe cardiac lesions. Deletion of JAG1 located in 20p12.2 is known to occur in ALGS and is associated with developmental delay, speech delay, intellectual disability, or poor coordination ^(28,29). It is also well-known that children with congenital heart disease demonstrate challenges in IQ, language, motor skills, attention, and executive function ^(30–33).

There were no significant differences in mean FSIQ among PFIC genotypes. Interestingly, while mean FSIQ among A1AT ZZ participants were similar to SZ, all but one participant with FSIQ<85 had the ZZ variant. The small sample size of these comparison groups should be noted; thus, our findings are not conclusive, but may be potentially clinically relevant.

There were several potential limitations. Completion of IQ testing was lower than planned for unknown reasons; time required for testing, scheduling challenges, and illness severity likely contributed. Our analysis is limited by small disease subgroups, which differed demographically and clinically. Our tested sample under-represents females (35%) compared with the eligible but untested group (49%); however, sex was not a significant univariate predictor of low FSIQ. High socioeconomic status (SES) across disease groups, reflected in parent education (69–88% with some college/trade school or more) is notable compared with the normative sample (approximately 55–60% for WPPSI-III and WISC-IV) ^(10,11). Additionally, because only patients with native liver were included, the study cohort may have skewed toward healthier participants, which suggests that our findings likely under-estimate concerns in this population. MHE status was not collected within the parent LOGIC study; hence, no correlation could be made with FSIQ. Although parental education was the only variable that remained significant after adjustment in the A1AT group, this should be interpreted with caution. Because the adaptive method assumes independence between all P values, it very likely leads to larger type 2 error, given that many of our risk factors were correlated. IQ testing represents only one instrument to assess neurocognitive ability, but is ubiquitously accepted, robust and reliable, provides some level of detail with composite scores, and represents a first step in characterizing these diseases on a large scale that has not been adequately captured previously. The WPPSI-III/WISC-IV tests were one version behind, which could have artificially inflated scores to some extent via the Flynn effect ⁽³⁴⁾. Note that the WPPSI-III and WISC-IV are not equivalent measures, although they are correlated almost at the same level as WISC-IV test-retest (r = 0.89 vs r = 0.93) ⁽¹¹⁾.

In conclusion, this is the first and largest prospective multi-center analysis of neurodevelopmental status in children with inherited cholestatic liver disorders who have not undergone liver transplantation. Our data show that children with ALGS are at increased risk of lower FSIQ but A1AT and PFIC are not. Both A1AT and ALGS appear to be more vulnerable to WMI and PSI deficits suggestive of attention and executive function impairment. Malnutrition, liver disease severity, and sociodemographic factors appear related to these FSIQ deficits. Lower albumin and higher alkaline phosphatase are associated with lower FSIQ in ALGS, potentially identifying nutrition as an important and early intervention. Early screening for and identification of neurodevelopmental deficits in children with ALGS should prompt therapies that can maximize developmental outcomes. Further, attention and executive functioning should be closely monitored across disease groups since these domains can significantly impact learning and everyday functioning.

Acknowledgments

Heather Van Doren, Senior Medical Editor with Arbor Research Collaborative for Health, provided editorial assistance on this manuscript. The authors thank the children and their families whose participation made this study possible.

REFERENCES

1. Kamath BM, Baker A, Houwen R, et al. The epidemiology, natural history, and burden of Alagille syndrome. J Pediatr Gastroenterol Nutr 2018; 67:148–156.

Cited Here |
View Full Text | PubMed | CrossRef

2. Mehl A, Bohorquez H, Serrano MS, et al. Liver transplantation and the management of progressive familial intrahepatic cholestasis in children. World J Transplant 2016; 6:278–290.

Cited Here

3. Teckman JH, Jain A. Advances in alpha-1-antitrypsin deficiency liver disease. Curr Gastroenterol Rep 2014; 16:367.

Cited Here |
PubMed | CrossRef

4. Spinner NB, Leonard LD, Krantz ID. Alagille syndrome. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. Gene Reviews. Seattle, WA; 1993. The Publisher is University of Washington, Seattle. GeneReviews^® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1273/

Cited Here

5. Alissa FT, Jaffe R, Shneider BL. Update on progressive familial intrahepatic cholestasis. J Pediatr Gastroenterol Nutr 2008; 46:241–252.

Cited Here |
View Full Text | PubMed | CrossRef

6. Perlmutter DH. Alpha-1-antitrypsin deficiency. Semin Liver Dis 1998; 18:217–225.

Cited Here |
PubMed | CrossRef

7. Riether AM, Smith SL, Lewison BJ, et al. Quality-of-life changes and psychiatric and neurocognitive outcome after heart and liver transplantation. Transplantation 1992; 54:444–450.

Cited Here |
View Full Text | PubMed | CrossRef

8. Robertson CM, Dinu IA, Joffe AR, et al. Neurocognitive outcomes at kindergarten entry after liver transplantation at <3 yr of age. Pediatr Transplant 2013; 17:621–630.

Cited Here |
View Full Text | PubMed

9. Rodijk LH, den Heijer AE, Hulscher JBF, et al. Neurodevelopmental outcomes in children with liver diseases: a systematic review. J Pediatr Gastroenterol Nutr 2018; 67:157–168.

Cited Here |
View Full Text | PubMed | CrossRef

10. Wechsler D. WPPSI-III Technical and Interpretive Manual. San Antonio, TX: The Psychological Corporation; 2002.

Cited Here

11. Wechsler D. The Wechsler Intelligence Scale for Children. The Psychological Corporation, 4th ed.San Antonio, TX: 2003.

Cited Here

12. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518–526.

Cited Here |
PubMed | CrossRef

13. Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317–1325.

Cited Here |
View Full Text | PubMed | CrossRef

14. CDC. A SAS program for the 2000 CDC growth charts (ages 0 to <20 years). Centers for Disease Control and Prevention; 2020. Available at: https://www.cdc.gov/nccdphp/dnpao/growthcharts/resources/sas.htm. [Accessed 16 January 2020]

Cited Here

15. Bass LM, Shneider BL, Henn L, et al. Clinically evident portal hypertension: an operational research definition for future investigations in the pediatric population. J Pediatr Gastroenterol Nutr 2019; 68:763–767.

Cited Here |
View Full Text | PubMed | CrossRef

16. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990; 9:811–818.

Cited Here |
PubMed | CrossRef

17. Ng VL, Sorensen LG, Alonso EM, et al. Neurodevelopmental outcome of young children with biliary atresia and native liver: results from the ChiLDReN study. J Pediatr 2018; 196:139–147. 133.

Cited Here |
View Full Text | PubMed | CrossRef

18. Gold A, Rogers A, Cruchley E, et al. Assessment of school readiness in chronic cholestatic liver disease: a pilot study examining children with and without liver transplantation. Can J Gastroenterol Hepatol 2017; 2017:9873945.

Cited Here |
PubMed

19. Kamath BM, Chen Z, Romero R, et al. Quality of life and its determinants in a multicenter cohort of children with Alagille syndrome. J Pediatr 2015; 167:390–396. e393.

Cited Here |
View Full Text | PubMed | CrossRef

20. Loomes KM, Spino C, Goodrich NP, et al. Bone density in children with chronic liver disease correlates with growth and cholestasis. Hepatology 2019; 69:245–257.

Cited Here |
View Full Text | PubMed | CrossRef

21. Kindler JM, Mitchell EL, Piccoli DA, et al. Bone geometry and microarchitecture deficits in children with Alagille syndrome. Bone 2020; 141:115576.

Cited Here |
PubMed | CrossRef

22. Youngstrom DW, Dishowitz MI, Bales CB, et al. Jagged1 expression by osteoblast-lineage cells regulates trabecular bone mass and periosteal expansion in mice. Bone 2016; 91:64–74.

Cited Here |
PubMed | CrossRef

23. McCann M, Bayliss DM, Pestell C, et al. The relationship between sleep and working memory in children with neurological conditions. Child Neuropsychol 2018; 24:304–321.

Cited Here |
PubMed | CrossRef

24. Rogers M, Hwang H, Toplak M, et al. Inattention, working memory, and academic achievement in adolescents referred for attention deficit/hyperactivity disorder (ADHD). Child Neuropsychol 2011; 17:444–458.

Cited Here |
PubMed | CrossRef

25. Korpela S, Nyman A, Munck P, et al. Working memory in very-low-birthweight children at the age of 11 years. Child Neuropsychol 2018; 24:338–353.

Cited Here |
PubMed | CrossRef

26. Elisofon SA, Emerick KM, Sinacore JM, et al. Health status of patients with Alagille syndrome. J Pediatr Gastroenterol Nutr 2010; 51:759–765.

Cited Here |
View Full Text | PubMed | CrossRef

27. Kamath BM, Abetz-Webb L, Kennedy C, et al. Development of a novel tool to assess the impact of itching in pediatric cholestasis. Patient 2018; 11:69–82.

Cited Here |
PubMed

28. Freitas EL, Gribble SM, Simioni M, et al. Maternally inherited partial monosomy 9p (pter --> p24.1) and partial trisomy 20p (pter --> p12) characterized by microarray comparative genomic hybridization. Am J Med Genet A 2011; 155A:2754–2761.

Cited Here |
View Full Text | PubMed

29. Oegema R, van Zutven LJ, van Hassel DA, et al. Unbalanced three-way chromosomal translocation leading to deletion 18q and duplication 20p. Eur J Med Genet 2012; 55:265–268.

Cited Here |
PubMed | CrossRef

30. Majnemer A, Limperopoulos C, Shevell MI, et al. A new look at outcomes of infants with congenital heart disease. Pediatr Neurol 2009; 40:197–204.

Cited Here |
PubMed | CrossRef

31. Wernovsky G. Current insights regarding neurological and developmental abnormalities in children and young adults with complex congenital cardiac disease. Cardiol Young 2006; 16: (Suppl 1): 92–104.

Cited Here |
View Full Text | PubMed | CrossRef

32. Cassidy AR, White MT, DeMaso DR, et al. Executive function in children and adolescents with critical cyanotic congenital heart disease. J Int Neuropsychol Soc 2015; 21:34–49.

Cited Here |
PubMed | CrossRef

33. Marelli A, Miller SP, Marino BS, et al. Brain in congenital heart disease across the lifespan: the cumulative burden of injury. Circulation 2016; 133:1951–1962.

Cited Here |
View Full Text | PubMed | CrossRef

34. Trahan LH, Stuebing KK, Fletcher JM, et al. The Flynn effect: a meta-analysis. Psychol Bull 2014; 140:1332–1360.

Cited Here |
View Full Text | PubMed | CrossRef

Keywords:

Alagille syndrome; alpha-1 antitrypsin deficiency; intelligence quotient; neurocognitive; progressive familial intrahepatic cholestasis

Supplemental Digital Content

Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition

Article Keywords

Keyword Highlighting
Highlight selected keywords in the article text.

	Alagille syndrome
	alpha-1 antitrypsin deficiency
	intelligence quotient
	neurocognitive
	progressive familial intrahepatic cholestasis

Secondary Logo

Journal Logo

Neurodevelopmental Outcomes in Children With Inherited Liver Disease and Native Liver

Abstract

Objective:

Methods:

Results:

Conclusions:

METHODS

Study Population

Intelligence Testing—Measures of Intelligence Quotient

Risk Factors

Statistical Methods

RESULTS

Study Population

Demographic and Clinical Variables

Intelligent Quotient Scores

Risk Factor Analysis

DISCUSSION

Acknowledgments

REFERENCES

Supplemental Digital Content

Article Level Metrics

Related Links

Article Keywords

Related Videos

Connect With Us

Readers Of this Article Also Read

Neurodevelopmental Outcomes in Children With Inherited Liver Disease and Native Liver : Journal of Pediatric Gastroenterology and Nutrition

Abstract

Objective:

Methods:

Results:

Conclusions:

METHODS

Study Population

Intelligence Testing—Measures of Intelligence Quotient

Risk Factors

Statistical Methods

RESULTS

Study Population

Demographic and Clinical Variables

Intelligent Quotient Scores

Risk Factor Analysis

DISCUSSION

Acknowledgments

REFERENCES

Supplemental Digital Content